Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 989 GBX 0.05% Market Closed
Market Cap: 4.4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hikma Pharmaceuticals PLC
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Short-Term Investments
$127m
CAGR 3-Years
8%
CAGR 5-Years
42%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Short-Term Investments
ÂŁ21m
CAGR 3-Years
-29%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
AstraZeneca PLC
LSE:AZN
Short-Term Investments
$160m
CAGR 3-Years
37%
CAGR 5-Years
-28%
CAGR 10-Years
-15%
Verona Pharma PLC
NASDAQ:VRNA
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Short-Term Investments
$77m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hikma Pharmaceuticals PLC
Glance View

Market Cap
4.4B GBX
Industry
Pharmaceuticals

Hikma Pharmaceuticals PLC, a Jordanian-British multinational, began its journey in the heart of Amman, Jordan, in 1978, founded by Samih Darwazah. Over the years, it has evolved from a local pharmaceutical manufacturer into a global powerhouse, recognized as a key player in the generic pharmaceutical industry. The company's core strategy revolves around the production and distribution of a wide array of generic medications, serving diverse therapeutic categories such as cardiovascular, oncology, and infectious diseases. Hikma's competitive edge lies in its ability to produce high-quality and cost-effective medicines, which are crucial in both high-demand regions and emerging markets where affordable healthcare options are often limited. By leveraging its robust manufacturing capabilities and regulatory expertise, Hikma efficiently supplies generic and branded medications to over 50 countries worldwide, nurturing its growth and bolstering its market position. Driving the gears of Hikma's revenue machine are its three main operational segments: Injectables, Generics, and Branded pharmaceuticals. The Injectables division, a significant contributor to its financial health, supplies hospitals with critical sterile products, benefiting especially when acute care needs surge. Meanwhile, the Generics division continues to expand its footprint in the U.S. market, offering cost-effective alternatives to brand-name drugs, riding the wave of patent expirations. The Branded segment, deeply rooted in the Middle East and North Africa, capitalizes on Hikma's regional expertise and trusted brand reputation. Through this diversified business model, Hikma not only fortifies its financial stability but also ensures resilience against market fluctuations, steering the firm towards sustainable growth amidst an ever-evolving global pharmaceutical landscape.

HIK Intrinsic Value
3 863.84 GBX
Undervaluation 49%
Intrinsic Value
Price

See Also

What is Hikma Pharmaceuticals PLC's Short-Term Investments?
Short-Term Investments
127m USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Short-Term Investments amounts to 127m USD.

What is Hikma Pharmaceuticals PLC's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
42%

Over the last year, the Short-Term Investments growth was -30%. The average annual Short-Term Investments growth rates for Hikma Pharmaceuticals PLC have been 8% over the past three years , 42% over the past five years .

Back to Top